Determination of the purity of pharmaceutical reference materials by 1H NMR using the standardless PULCON methodology

Journal of Pharmaceutical and Biomedical Analysis

Volumn 100, Issue , 2014, Pages 381-386

  Monakhova, Yulia B ^a,b,c   Kohl Himmelseher, Matthias ^a   Kuballa, Thomas ^a   Lachenmeier, Dirk W ^a  

^a Chemisches und Veterinäruntersuchungsamt ^*  (Germany)

^b BRUKER BIOSPIN GMBH   (Germany)

^c SARATOV STATE UNIVERSITY   (Russian Federation)

Author keywords

1H NMR; Amantadine; Ambroxol; Ibandronic acid; PULCON methodology

Indexed keywords

AMANTADINE; AMBROXOL; IBANDRONIC ACID; LERCANIDIPINE; BISPHOSPHONIC ACID DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; DRUG;

ACCURACY; ARTICLE; DRUG MANUFACTURE; DRUG PURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHODOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; PULSE LENGTH BASED CONCENTRATION DETERMINATION METHOD; STANDARD; CALIBRATION; CHEMICAL MODEL; DRUG CONTAMINATION; PHARMACEUTICS; PROCEDURES; REPRODUCIBILITY; STANDARDS; VALIDATION STUDY;

AMANTADINE; AMBROXOL; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROPYRIDINES; DIPHOSPHONATES; DRUG CONTAMINATION; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84908570705     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.08.024     Document Type: Article

References (43)

1. Holzgrabe U. Quantitative NMR spectroscopy in pharmaceutical applications. Prog. Nucl. Magn. Reson. Spectrosc. 2010, 56:229-240.
2. 1H NMR determination of pharmacologically active substances in dietary supplements and medicines that have been illegally traded over the Internet. Drug Test. Anal. 2013, 5:400-411.
3. Malet-Martino M., Holzgrabe U. NMR techniques in biomedical and pharmaceutical analysis. J. Pharm. Biomed. Anal. 2011, 55:1-15.
4. 1H NMR. J. Pharm. Biomed. Anal. 2014, 93:156-160.
5. 1H NMR spectroscopy. J. Agric. Food Chem. 2014, 62:2506-2515.
6. Wider G., Dreier L. Measuring protein concentrations by NMR spectroscopy. J. Am. Chem. Soc. 2006, 128:2571-2576.
7. Cullen C.H., Ray G.J., Szabo C.M. A comparison of quantitative nuclear magnetic resonance methods: internal, external, and electronic referencing. Magn. Reson. Chem. 2013, 51:705-713.
8. Akoka S., Barantin L., Trierweiler M. Concentration measurement by proton NMR using the ERETIC method. Anal. Chem. 1999, 71:2554-2557.
9. 1H NMR method. Mar. Drugs. 2013, 11:3742-3753.
10. 1H NMR method. J. Pharm. Biomed. Anal. 2012, 60:44-50.
11. 1H NMR ERETIC method. Carbohydr. Res. 2006, 341:1890-1895.
12. Ziarelli F., Caldarelli S. Solid-state NMR as an analytical tool: quantitative aspects. Solid State Nucl. Magn. Reson. 2006, 1-3:214-218.
13. Ziarelli F., Viel S., Sanchez S., Cross D., Caldarelli S. Precision and sensitivity optimization of quantitative measurements in solid state NMR. J. Magn. Reson. 2007, 188:260-266.
14. 1H MRS and the Electric REference To access In vivo Concentrations (ERETIC) method. NMR Biomed. 2010, 23:406-413.
15. Martínez-Bisbal M.C., Monleon D., Assemat O., Piotto M., Piquer J., Llácer J.L., Celda B. Determination of metabolite concentrations in human brain tumour biopsy samples using HR-MAS and ERETIC measurements. NMR Biomed. 2009, 22:199-206.
16. Michel N., Akoka S. The application of the ERETIC method to 2D-NMR. J. Magn. Reson. 2004, 168:118-123.
17. Van Lokeren L., Kerssebaum R., Willem R., Denkova P. ERETIC implemented in diffusion-ordered NMR as a diffusion reference. Magn. Reson. Chem. 2008, 46:S63-S71.
18. Ziarelli F., Viel S., Caldarelli S., Sobieski D.N., Augustine M.P. General implementation of the ERETIC method for pulsed field gradient probe heads. J. Magn. Reson. 2008, 194:307-312.
19. Hoult D.I. The principle of reciprocity. J. Magn. Reson. 2011, 213:344-346.
20. Farrant R.D., Hollerton J.C., Lynn S.M., Provera S., Sidebottom P.J., Upton R.J. NMR quantification using an artificial signal. Magn. Reson. Chem. 2010, 48:753-762.
21. Dreier L., Wider G. Concentration measurements by PULCON using X-filtered or 2D NMR spectra. Magn. Reson. Chem. 2006, 44:S206-S212.
22. Köbler H., Monakhova Y.B., Kuballa T., Tschiersch C., Vancutsem J., Thielert G., Mohring A., Lachenmeier D.W. Use of nuclear magnetic resonance spectroscopy and chemometrics to identify pine nuts that cause taste disturbance. J. Agric. Food Chem. 2011, 59:6877-6881.
23. 1H NMR spectroscopy. Drug Test. Anal. 2014, 10.1002/dta.1677.
24. McCormack P.L., Plosker G.L. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs 2006, 66:711-728.
25. Rossini M., Orsolini G., Adami S., Kunnathully V., Gatti D. Osteoporosis treatment: why ibandronic acid?. Expert Opin. Pharmacother. 2013, 14:1371-1381.
26. Sparidans R.W., den Hartigh J., Cremers S., Beijnen J.H., Vermeij P. Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate. J. Chromatogr. B. Biomed. Sci. Appl. 2000, 738:331-341.
27. Endele R., Loew H., Bauss F. Analytical methods for the quantification of ibandronate in body fluids and bone. J. Pharm. Biomed. Anal. 2005, 39:246-256.
28. Tarcomnicu I., Gheorghe M.C., Silvestro L., Savu S.R., Boaru I., Tudoroniu A. High-throughput HPLC-MS/MS method to determine ibandronate in human plasma for pharmacokinetic applications. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:3159-3168.
29. Rodríguez J.A., Desimone M.F., Iglesias S.L., Giorgieri S.A., Diaz L.E. Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities. J. Pharm. Biomed. Anal. 2007, 44:305-308.
30. Seo S., Englund J.A., Nguyen J.T., Pukrittayakamee S., Lindegardh N., Tarning J., Tambyah P.A., Renaud C., Went G.T., de Jong M.D., Boeckh M.J. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir. Ther. 2013, 18:377-386.
31. Malkani R., Zadikoff C., Melen O., Videnovic A., Borushko E., Simuni T. Amantadine for freezing of gait in patients with Parkinson disease. Clin. Neuropharmacol. 2012, 35:266-268.
32. Yan H., Liu X., Cui F., Yun H., Li J., Ding S., Yang D., Zhang Z. Determination of amantadine and rimantadine in chicken muscle by QuEChERS pretreatment method and UHPLC coupled with LTQ Orbitrap mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 938:8-13.
33. Farajzadeh M.A., Nouri N., Alizadeh Nabil A.A. Determination of amantadine in biological fluids using simultaneous derivatization and dispersive liquid-liquid microextraction followed by gas chromatography-flame ionization detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 930:142-149.
34. Saraji M., Khayamian T., Mirmahdieh S., Bidgoli A.A. Analysis of amantadine in biological fluids using hollow fiber-based liquid-liquid-liquid microextraction followed by corona discharge ion mobility spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879:3065-3070.
35. Wang G.Q., Qin Y.F., Du L.M., Li J.F., Jing X., Chang Y.X., Wu H. Determination of amantadine and rimantadine using a sensitive fluorescent probe. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2012, 98:275-281.
36. Malerba M., Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 2008, 4:1119-1129.
37. Abdelwahab N.S. Determination of ambroxol hydrochloride, guaifenesin, and theophylline in ternary mixtures and in the presence of excipients in different pharmaceutical dosage forms. J. AOAC Int. 2012, 95:1629-1638.
38. Dharuman J., Vasudhevan M., Ajithlal T. High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine - a boxcar approach. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879:2624-2631.
39. Emara S., Kamal M., Abdel Kawi M. On-line sample cleanup and enrichment chromatographic technique for the determination of ambroxol in human serum. J. Chromatogr. Sci. 2012, 50:91-96.
40. Muralidharan S., Kumar J.R., Dhanara S.A. Development and validation of an high-performance liquid chromatographic, and a ultraviolet spectrophotometric method for determination of Ambroxol hydrochloride in pharmaceutical preparations. J. Adv. Pharm. Technol. Res. 2013, 4:65-68.
41. Cicero A.F., Gerocarni B., Rosticci M., Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin. Exp. Hypertens 2012, 34:113-117.
42. Kaila H.O., Ambasana M.A., Thakkar R.S., Saravaia H.T., Shah A.K. A stability-indicating HPLC method for assay of lercanidipine hydrochloride in tablets and for determining content uniformity. Indian J. Pharm. Sci. 2010, 72:381-384.
43. Oztürk F., Taşdemir I.H., Erdoğan D.A., Erk N., Kiliç E. A new voltammetric method for the determination of lercanidipine in biological samples. Acta Chim. Slov. 2011, 58:830-839.